European Urology Oncology Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy  Anis A. Hamid, Kathryn P. Gray, Ying Huang, Michaela Bowden, Mark Pomerantz, Massimo Loda, Christopher J. Sweeney  European Urology Oncology  DOI: 10.1016/j.euo.2018.09.003 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 PTEN and AMACR (tumor masking) fluorescent immunostaining of tissue microarray cores. (A) Positive (intact) PTEN staining of prostate cancer glands (arrow) that also expressed cytoplasmic AMACR (B, arrow). (C) Absent PTEN in tumor glands (arrows) with positive AMACR (D, arrows) for comparison. (E) Normal prostate tissue with positive PTEN staining of benign glands and stroma. (F) Normal prostate tissue demonstrates a lack of AMACR expression. European Urology Oncology DOI: (10.1016/j.euo.2018.09.003) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier estimates of (A) time to metastasis and (B) overall survival. PTEN expression (nuclear plus cytoplasmic) was analyzed dichotomously, with low indicating expression in the lowest quartile for the cohort and high indicating expression greater than that in the lowest quartile. HR=hazard ratio; CI=confidence interval. European Urology Oncology DOI: (10.1016/j.euo.2018.09.003) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Comparison of receiver operating characteristic curves for prediction of (A) metastatic disease and (B) death at 10 yr using clinicopathologic factors, PTEN expression (nuclear and cytoplasmic), or a combination of clinicopathologic factors and PTEN expression. AUC=area under the curve. European Urology Oncology DOI: (10.1016/j.euo.2018.09.003) Copyright © 2018 European Association of Urology Terms and Conditions